STOK (Stoke Therapeutics) Current Accrued Expense: $18.49 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STOK Stoke Therapeutics Inc STOK
45 GF Score
Price $31.86
GF Value $9.64
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Stoke Therapeutics Current Accrued Expense?

Stoke Therapeutics STOK +1.87% 45 Current Accrued Expense is $18.49 Mil as of Jun. 2026. GuruFocus rates STOK with a GF Score™ of 45/100 and a GF Value™ of $9.64 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Stoke Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was $18.49 Mil.

Stoke Therapeutics's quarterly Current Accrued Expense declined from Dec. 2025 ($22.99 Mil) to Mar. 2026 ($16.89 Mil) but then increased from Mar. 2026 ($16.89 Mil) to Jun. 2026 ($18.49 Mil).

Stoke Therapeutics's annual Current Accrued Expense increased from Dec. 2023 ($5.29 Mil) to Dec. 2024 ($7.81 Mil) and increased from Dec. 2024 ($7.81 Mil) to Dec. 2025 ($22.99 Mil).

Stoke Therapeutics Current Accrued Expense Related Terms

Stoke Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Stoke Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stoke Therapeutics Current Accrued Expense Chart

Stoke Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only 7.32 7.13 5.29 7.81 22.99

Stoke Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.46 19.17 22.99 16.89 18.49
STOK
45GF Score
Stoke Therapeutics Inc STOK
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stoke Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $18.49 Mil mean?
Stoke Therapeutics (STOK) has a Current Accrued Expense of $18.49 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Stoke Therapeutics and its competitors.
Is Stoke Therapeutics' Current Accrued Expense too high?
Stoke Therapeutics' current Current Accrued Expense is $18.49 Mil. Overall, Stoke Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' Current Accrued Expense compare to TYRA and SNDX?
Stoke Therapeutics' Current Accrued Expense of $18.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Stoke Therapeutics and its competitors. Stoke Therapeutics's current Current Accrued Expense is $18.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.64, compared to a current price of $31.86 — trading 230.4% above its estimated fair value. The current Current Accrued Expense is $18.49 Mil. Stoke Therapeutics' overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current Current Accrued Expense is $18.49 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stoke Therapeutics (STOK) Overvalued in 2026?

Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued. The current stock price of $31.86 is trading 230.4% above its estimated GF Value™ of $9.64. GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.

Key valuation signals for STOK:

  • Current Accrued Expense: $18.49 Mil
  • GF Value™: $9.64 vs. price of $31.86 (230.4% above fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Stoke Therapeutics Business Description

Other Exchanges 0GT:Germany
Address 45 Wiggins Avenue, Bedford, MA, USA, 01730
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
45GF Score

Get the complete analysis for STOK

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.86
Price
$9.64
GF Value